5 results about "Adeno associate virus" patented technology

Described herein is an immortalized mammalian cell configured for production of a bioproduct of interest, which cell has a safe harbor locus selected from an Adeno Associated Virus 1 (AAVS1) locus, a CCR5 locus, and a Rosa26 locus into which a Human Papillomavirus (HPV) E6 gene sequence and an HPV E7 gene sequence have been inserted. Also disclosed herein are methods for immortalizing a mammalian cell for production of a bioproduct of interest as well as methods of producing a bioproduct of interest.

Disclosed herein are nucleic acid molecules and compositions of preparing recombinant adeno-associated viruses (rAAV) and uses thereof. Specifically, two-plasmid systems are provided for efficient rAAV production.

Provided are a mutant of an adeno-associated virus (AAV) targeting a resting or activated T cell, a use of the mutant of the AAV, and a heterologous peptide targeting a T cell. An amino acid sequence of the heterologous peptide is set forth in any one of SEQ ID NOS: 1-5. The mutant of the AAV exhibits high efficiency in targeting resting or activated T cells, and has advantages such as low dose, strong infectivity, and high safety. A recombinant adeno-associated virus (rAAV) can be constructed from a mutant of an AAV capsid protein of the present application. Nucleic acid sequences carried by rAAV can not be integrated into the genome of the host cell. T he rAAV can be used for the quick infection and reinfusion of activated T cells, which reduces the unnecessary quality control and in vitro dwell time.

Provided herein are pharmaceutical compositions comprising an adeno-associated virus (AAV). In some aspects, a pharmaceutical composition comprises from about 5 mM to about 20 mM of a Tris buffer, from about 100 mM to about 250 mM of sodium chloride, from about 0.001% (w / v) to about 0.01% (w / v) of Pluronic F68, and has a pH of from 7.0 to 9.0. Also provided are methods of making a pharmaceutical composition comprising the AAV, methods of treating a VEGF-associated condition in a subject, and methods of storing the AAV composition.

This disclosure provides methods for identifying a subject suitable for an adeno associated virus (AAV) therapy. In some embodiments, the method comprises measuring a titer of an antibody or antigen-binding portion thereof that specifically binds to an AAV (“anti-AAV antibody”) in a biological sample obtained from the subject using an enzyme-linked immunosorbent assay (ELISA).